Brooklyn: Phase II Results of IRX-2
ADC评论
July 28, 2022
On July 26, Brooklyn announced results from the Phase II INSPIRE trial of IRX-2, a multi-cytokine biological immunotherapy. The trial was designed to evaluate the
